Assessing Cencora (COR) Valuation After Recent Share Pullback And Premium P/E Multiple

Simply Wall St.04-27 20:09

AdvertisementCencora overview and recent share performance Cencora (COR) has drawn investor attention after a period of mixed share performance, with the stock showing a 1 day return of 1.03%, a 7 day...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2630397832?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/24809-main-header/1756252652273","is_english":true,"pubTime":"2026-04-27 20:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2630397832","market":"nz","top_or_hot":-1,"title":"Assessing Cencora (COR) Valuation After Recent Share Pullback And Premium P/E Multiple","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementCencora overview and recent share performance Cencora (COR) has drawn investor attention after a period of mixed share performance, with the stock showing a 1 day return of 1.03%, a 7 day...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-cor/cencora/news/assessing-cencora-cor-valuation-after-recent-share-pullback\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Cencora (COR) Valuation After Recent Share Pullback And Premium P/E Multiple</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Cencora (COR) Valuation After Recent Share Pullback And Premium P/E Multiple\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-27 20:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-cor/cencora/news/assessing-cencora-cor-valuation-after-recent-share-pullback><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementCencora overview and recent share performance Cencora (COR) has drawn investor attention after a period of mixed share performance, with the stock showing a 1 day return of 1.03%, a 7 day...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-cor/cencora/news/assessing-cencora-cor-valuation-after-recent-share-pullback\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4529","symbol_name":"IDC概念","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-cor/cencora/news/assessing-cencora-cor-valuation-after-recent-share-pullback","article_id":"2630397832","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/24809-main-header/1756252652273"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-cor/cencora/news/assessing-cencora-cor-valuation-after-recent-share-pullback","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2630397832","pubTimestamp":1777291774,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Cencora overview and recent share performance\nCencora (COR) has drawn investor attention after a period of mixed share performance, with the stock showing a 1 day return of 1.03%, a 7 day decline of 4.59%, and a past 3 months decline of 13.46%.\nOver a longer horizon, Cencora has a 1 year total return of 7.87%, a 3 year total return that is very large, and a 5 year total return of 1.62x, with the shares last closing at US$308.19.\nSee our latest analysis for Cencora.\nRecent share price moves...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4529":"IDC概念","LU0058720904.USD":"联博国际健康护理基金A","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","BK4175":"保健护理产品经销商","LU1261432733.SGD":"Fidelity World A-ACC-SGD","SG9999004303.SGD":"Nikko AM Shenton Global Opportunities SGD","LU1814569148.SGD":"WELLINGTON GLOBAL QUALITY GROWTH \"D\" (SGDHDG) ACC","LU1084165304.USD":"FIDELITY WORLD \"A\" (USD) ACC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","BK4588":"碎股","LU2237957902.USD":"NIKKO AM GLOBAL EQUITY \"F\" (USD) ACC","LU1119994496.HKD":"FIDELITY WORLD \"A\" (HKD) ACC","SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","LU2237957811.SGD":"NIKKO AM GLOBAL EQUITY \"F\" (SGD) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","COR":"CENCORA","BK4585":"ETF&股票定投概念","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","BK4084":"特种房地产投资信托"},"translate_title":"在最近股价回调和溢价市盈率倍数后评估Cencora(COR)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"COR":1.5},"content_text":"AdvertisementCencora overview and recent share performance Cencora (COR) has drawn investor attention after a period of mixed share performance, with the stock showing a 1 day return of 1.03%, a 7 day decline of 4.59%, and a past 3 months decline of 13.46%. Over a longer horizon, Cencora has a 1 year total return of 7.87%, a 3 year total return that is very large, and a 5 year total return of 1.62x, with the shares last closing at US$308.19. See our latest analysis for Cencora. Recent share price moves have been soft, with the stock showing declines over the past week, quarter, and year to date, even as multi year total shareholder returns remain strong. This signals fading momentum after a solid longer term run. If Cencora’s recent pullback has you thinking about where else capital could work hard, this is a good moment to scan 33 healthcare AI stocks. So with Cencora’s recent pullback, solid multiyear total returns, and signs of an intrinsic discount, are you looking at an undervalued healthcare distributor, or a stock where the market has already priced in future growth? Most Popular Narrative: 23.5% Undervalued Cencora’s most followed valuation narrative sets fair value at $402.92 per share, well above the last close at $308.19. This frames a sizeable implied discount before you even look at the underlying assumptions.  Cencora's ongoing investment in digital infrastructure and advanced analytics positions the company to capitalize on the accelerating digitization of healthcare and regulatory requirements like the Drug Supply Chain Security Act. These developments may improve supply chain efficiency and transparency, which could support higher net margins and operating income over time.  Read the complete narrative. Want to see what kind of revenue run rate, margin lift, and long term earnings profile this story is built on? The fair value hinges on a specific set of growth assumptions, a richer profit profile, and a future earnings multiple that needs to line up with those forecasts. Curious which of those levers accounts for most of the $402.92 figure? Result: Fair Value of $402.92 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this hinges on higher margin expectations and a rebound in international operations, and regulatory pressure on drug pricing could easily challenge both parts of that story. Find out about the key risks to this Cencora narrative. Another View: Market Multiple Sends A Different Signal That fair value story sits awkwardly beside the current P/E of 36.9x, which is well above both the US Healthcare sector on 24.3x and a fair ratio of 33.5x. In simple terms, the market is already paying a premium. Is that a cushion or a cliff if expectations shift? To see how that premium lines up with earnings quality, debt levels, and analyst assumptions, take a closer look at See what the numbers say about this price — find out in our valuation breakdown. NYSE:COR P/E Ratio as at Apr 2026Next Steps With sentiment clearly split between upside potential and richer pricing, this is the moment to look at the underlying data yourself and move quickly. To weigh these trade offs directly, start by reviewing the 4 key rewards and 2 important warning signs. Ready to act on your next idea? If Cencora has sharpened your thinking, do not stop here. Put that momentum to work by scanning fresh ideas tailored to different investing goals.  Target potential mispricing across the market and see which companies stand out on value by running the 54 high quality undervalued stocks. Strengthen the income side of your portfolio by focusing on companies that meet a higher yield hurdle with the 12 dividend fortresses. Reduce portfolio anxiety by zeroing in on companies that score well on resilience using the 72 resilient stocks with low risk scores.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2630397832","isCrawlerRequest":true}